The Alzheimer's Drug Discovery Foundation supports scientists working on new treatments for Alzheimer's disease. We fund research programs, organize conferences, and provide expertise to accelerate drug discovery and development.
The ADDF is focused on translational research—translating the knowledge we have gained about the underlying causes of Alzheimer’s disease into drugs. We fund programs in academia and biotechnology companies worldwide, with priority funding in drug discovery and preclinical drug development, clinical trials, and early detection. Learn more by reviewing our research priorities and by reading our current requests for proposals (RFPs).
The ADDF enables critical knowledge sharing by organizing and sponsoring scientific conferences around the globe. Our conferences bring together leaders and young scientists from academia, the pharmaceutical industry, biotechnology companies, and contract research organizations to network and generate partnerships. We also convene advisory panels focused on key issues in drug discovery and development for Alzheimer's and related dementias.
Drug discovery is a team effort, requiring collaboration between scientists in different fields, from biology and chemistry to pharmacology. To help scientists find guidance and resources to accelerate projects through the drug discovery process, we created the ADDF ACCESS program. This website connects Alzheimer’s scientists with a vetted network of contract research organizations (CROs) and consultants and a library of educational resources.
The ADDF’s Aging and Alzheimer's Prevention program evaluates, communicates, and accelerates the science of Alzheimer’s and cognitive-aging prevention. Our scientists assess the scientific evidence for and against therapies to prevent brain aging or dementia, and share these findings on our site, Cognitive Vitality, and in peer-reviewed scientific articles. Through the program, the ADDF also organizes advisory panels and funds research to accelerate the development of prevention therapies.